Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.







APA-OTS-Meldungen aus dem Finanzsektor in der "BSN Extended Version"
Wichtige Originaltextaussendungen aus der Branche. Wir ergänzen vollautomatisch Bilder aus dem Fundus von photaq.com und Aktieninformationen aus dem Börse Social Network. Wer eine Korrektur zu den Beiträgen wünscht: mailto:office@boerse-social.com . Wir wiederum übernehmen keinerlei Haftung für Augenerkrankungen aufgrund von geballtem Grossbuchstabeneinsatz der Aussender. Wir meinen: Firmennamen, die länger als drei Buchstaben sind, schreibt man nicht durchgängig in Grossbuchstaben (Versalien).
Magazine aktuell


#gabb aktuell



19.11.2020, 12845 Zeichen

Corporate news transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.– annual forecast increased several times due to pandemic-related exceptionalboom and...

...successesQuarterly ReportVienna -Consolidated revenue slightly increases by 0.8% to EUR 657.2 million\nStrong increase in revenue in the Medical Sector (+27.5%) somewhat overcompensated the decrease in the Industrial Sector (-13.4%) in absolute figures\nEBITDA almost doubled to EUR 118.5 million; EBITDA margin at 18.0% after 9.3% also almost twice as high\nEBIT significantly improved to EUR 159.9 million in the first three quarters due to reversal of impairment in the Sempermed segment; EBIT margin increased from -2.1% to 24.3%\nAdjusted EBIT of EUR 92.6 million more than tripled\nAnnual forecast for 2020 repeatedly revised upwards\nEarly repayment of hybrid capital planned\n19 November 2020 - As a result of the pandemic-related exceptional boom inmedical protective gloves, the consistent restructuring and transformationprocess over several years and the strict and immediate cost-cutting measures tocontain the negative external market shock caused by CoViD-19 in the IndustrialSector, the Semperit Group achieved a record result in the first nine months of2020 while at the same time significantly increasing the Group's liquidity. "Sofar, Semperit has very successfully coped with the year 2020, which ischaracterised by an absolutely exceptional situation: this has become visible,among other things, in the three-fold improvement in the earnings forecast andour plan to repay the hybrid capital within the next six months," says MartinFüllenbach, CEO of Semperit AG Holding.Further earnings improvement possible in 2021"The positive developments are primarily due to the exceptional boom in medicalproducts. However, they are also the result of comprehensive restructuringmeasures as well as stringent crisis management throughout the Semperit Group,"Füllenbach continued. "Even if a broadly effective vaccine against CoViD-19becomes available in the foreseeable future, we will experience pandemic-relatedpositive effects from the medical business well into 2021: all in all, fromtoday's point of view, our planning is therefore based on the assumption that wewill be able to maintain the 2020 result in the coming year at the same range oreven surpass it again."Slow market recovery expectedAlthough a brief recovery of economic activities and supply chains began betweenJune and September following the easing of production freeze in many countriesand the disruption of public life, there were repeated setbacks and, in somecases, new shutdowns due to regional corona clusters. As the crisis intensifiesagain in the fourth quarter, the recovery of the markets will take even longerwith increasing raw material prices. The prices of basic raw materials relevantto Semperit have risen sharply in recent months. These market-relevant externalfactors will continue to impact the business of the Semperit Group.Opposing revenue trends in Industrial and Medical SectorsThe results of the Industrial Sector have been reported under the new structuresince 1 January 2020. The Sector now consists of four segments (Semperflex,Sempertrans, Semperseal and Semperform), after Semperform was divided into twoseparate segments: Semperseal deals with sealing profiles and elastomer sheets,while Semperform comprises the business units handrails, cable car rings, skifoils and Engineered Solutions (SES).In the first three quarters of 2020, the Semperit Group recorded a slightincrease of 0.8% to EUR 657.2 million compared with the same period of theprevious year. The corona pandemic again had opposite effects on the SemperitGroup's Industrial and Medical Sectors: in the Industrial Sector, revenuedeclined by 13.4%, while the Medical Sector recorded an increase of 27.5%.Record result with high liquidityEBITDA almost doubled in the first three quarters from EUR 60.4 million in 2019to EUR 118.5 million in 2020. This is particularly due to the good result of theMedical Sector, which is based on the exceptional economic boom caused by thecorona pandemic on the one hand and on the successful restructuring andtransformation measures on the other. The EBITDA margin rose accordingly from9.3% to 18.0%. Compared to the EBITDA of EUR 56.4 million in the first threequarters of 2019, adjusted for the reversal of provisions of EUR 4.0 million,EBITDA was more than twice as high in the same period of 2020.At the end of the second quarter, the outbreak of the corona pandemic, whichoccurred during a phase of global economic slowdown, made it necessary toexamine all segments of the Semperit Group for the existence of observableindications of an impairment of segment assets. For the Sempermed andSempertrans segments, this examination resulted in a reversal of impairment (ofEUR 86.7 million) and an impairment loss (of EUR -19.9 million), which werealready recognised in the first half of the year.EBIT improved to EUR 159.5 million in the first three quarters of 2020, comparedto EUR -13.7 million in the first three quarters of 2019. The EBIT margin rosefrom -2.1% to 24.3%. EBIT adjusted for the reversal of impairment and impairmentlosses was EUR 92.6 million, more than three times as high as in the first threequarters of 2019 (EUR 29.0 million). At 14.1%, the adjusted EBIT margin was alsoaround three times the value for the comparable period.At EUR 17.4 million, cash-relevant investments in tangible and intangible assetsin the first three quarters were below the previous year's level of EUR 25.1million. As of 30 September 2020, cash and cash equivalents amounted to EUR157.3 million, up from EUR 141.4 million at the end of 2019. The increaseresulted from higher profitability - above all in the Sempermed segment.Restructuring measures make Industrial Sector resilientThe Industrial Sector was impacted by both the economic downturn that has beenapparent since 2019 and the corona effects. Revenue in the Sector therefore fellby -13.4% from EUR 426.2 million to EUR 369.0 million. The previously introducedrestructuring and transformation measures - as well as the measures to combatthe corona pandemic, increased customer proximity, even in the crisis situation,and strict cost management - partially offset the negative effects.The Industrial Sector was well prepared for the economic slowdown in 2020.Profitability was slightly above the previous year's level and therefore showeda resilient performance. Although EBITDA declined by -12.6% to EUR 65.3 milliondue to the decline in revenue, the EBITDA margin rose slightly to 17.7% in thefirst three quarters of 2020. EBIT declined by 51.1% to EUR 26.9 million and theEBIT margin fell from 12.9% to 7.3% in the first three quarters of 2020. At EUR46.8 million, adjusted EBIT was 14.9% below the previous year's level; at 12.7%,the adjusted EBIT margin was only slightly below the comparable value.Medial Sector: strengthened by restructuring and high demandThe development of the Sempermed segment in the first nine months of 2020 wascharacterised by two key factors. On the one hand, production volumes andoperational efficiency were increased as a result of the successfulrestructuring and transformation measures. On the other hand, as a result of thecorona pandemic, the significant increase in demand for examination andprotective gloves as well as surgical gloves - especially since the secondquarter - and the market-driven rise in price levels were decisive for theresult. Sales volumes rose significantly, with revenue growing by 27.5% to EUR288.2 million compared to the previous year.In addition to the positive corona effect, the measures of the restructuring andtransformation process in the Medical Sector showed their positive effects notonly in terms of production volume and increase in revenue, but also in terms ofproductivity and profitability: in the first three quarters of 2020, EBITDA wasEUR 67.3 million after EUR 5.6 million in the first three quarters of 2019,which also included a positive one-off effect of EUR 4.0 million from thereversal of a provision for tax proceedings relating to levies in Brazil. As aresult of the additional positive effect of the reversal of impairments, EBITamounted to EUR 147.5 million after EUR -47.2 million in the first threequarters of 2019, when an impairment loss of EUR 46.8 million had to berecorded. The EBIT adjusted for the reversal of impairment also improvedsignificantly to EUR 60.7 million compared to the adjusted EBIT of the previousyear (EUR -4.5 million), while the adjusted EBIT margin of 21.1% was above theprevious year's level (in the first three quarters of 2019: -2.0%).OutlookThe recessive economic development and the effects of the corona crisis lead toopposing developments in the Industrial and Medical Sectors: In the medicalprotective gloves business, a significant increase in demand and a sharp rise inprices have been observed since the outbreak of the corona crisis.The emerging effects of the global pandemic are considered to be of limitedsustainability. For this reason, the fundamental strategic decision of 28January 2020, according to which Semperit will focus on the industrial rubberbusiness in the future and separate from the medical business, is still valid,regardless of the developments recently observed in the wake of the coronacrisis. However, in view of the extremely positive earnings contributions andthe high margins that are currently resulting from the exceptional economicsituation, the Semperit Group will probably continue the medical business atleast until mid-2021.The Industrial Sector was hit by the global recession, which has worsened inrecent months due to the corona crisis. The results of the Industrial Sector inthe current year will therefore be noticeably below the previous year's level.The accelerating CoViD pandemic has a more positive effect on the demand andprice of medical products than expected in the first half of 2020. Against thisbackground and assuming the continued uninterrupted availability of rawmaterials, current figures indicate that the Semperit Group's EBITDA for thefull year will range between EUR 200.0 and 225.0 million and thus significantlyexceed the previous year's figure. The Semperit Group's EBIT is thereforeexpected to be between EUR 230.0 and 255.0 million for the full year 2020.In the first three quarters, the boom in the Medical Sector had positive effectson the liquidity of the Semperit Group. The Executive Board of Semperit AGHolding therefore plans to repay the hybrid capital made available by the coreshareholder B & C Holding Österreich GmbH within the next six months.The restructuring and transformation process initiated by the Semperit Group atthe beginning of 2018, which has led to significant improvements at variouslevels, has been further accelerated by the corona crisis. In this context, thefocus on cost-cutting measures will be sharpened again in the coming months.The Semperit management continues to monitor the situation very closely. Thegreatest threat is that a critical number of employees in key areas of the valuechain at one location may not be available due to infection with the coronavirus. In the Industrial Sector, the greatest discernible risk comes frompotential slumps in demand. In the Medical Sector, the current positivedevelopment may be slowed down by the early availability of a vaccine or themarket entry of new competitors. Ensuring the availability of raw materialsdepends on external factors and is the focus of the Semperit Group's purchasingorganisation. The decision on the payment of a dividend for 2020 is yet to bemade. In addition, the Executive Board of Semperit AG Holding now plans to repaythe hybrid capital provided by the core shareholder B & C Holding ÖsterreichGmbH within the next six months.From today's perspective, the outlook for 2021 is also positive: even if abroadly effective vaccine against CoViD-19 becomes available in the foreseeablefuture, the pandemic-related positive effects from the medical business areexpected to extend well into 2021. Based on planning assumptions, the ExecutiveBoard assumes from today's perspective that the 2020 result may be maintained atthe same level or even exceeded in the coming year.end of announcement euro adhocissuer: Semperit AG Holding Modecenterstrasse 22 A-1030 Wienphone: +43 1 79 777-310FAX: +43 1 79 777-602mail: judit.helenyi@semperitgroup.comWWW: www.semperitgroup.comISIN: AT0000785555indexes: WBI, ATX GP, ATX PRIMEstockmarkets: Wienlanguage: EnglishDigital press kit: http://www.ots.at/pressemappe/2918/aom

Börse Social Network Subscription

Um diesen Artikel zu lesen, müssen Sie eine Mitgliedschaft erwerben.

Tagespass 8.00 Euro /einmalig

15.00 Euro /monatlich



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Austrian Stocks in English: ATX drops Week 48, Rosinger Group receives Award from the EU, hear a live entry into the ceremony




Semperit
Akt. Indikation:  19.16 / 19.26
Uhrzeit:  18:58:35
Veränderung zu letztem SK:  0.16%
Letzter SK:  19.18 ( 0.10%)



 

Bildnachweis

1. Judit Helenyi, Semperit AG Holding , (© CIRA/APA-Fotoservice/Bargad Fotograf/in: Nadine Bargad)   >> Öffnen auf photaq.com

Aktien auf dem Radar:Telekom Austria, FACC, OMV, Addiko Bank, Flughafen Wien, Amag, Frequentis, Mayr-Melnhof, AMS, S Immo, VIG, Wienerberger, Andritz, Kostad, Lenzing, Warimpex, Oberbank AG Stamm, Erste Group, Österreichische Post, Polytec Group, RBI, Rosenbauer, Uniqa, voestalpine, Zalando, Airbus Group, SAP, Fresenius Medical Care, Henkel, Deutsche Boerse, Beiersdorf.


Random Partner

S&T AG
Der Technologiekonzern S&T AG ist mit rund 6.300 Mitarbeitern und Niederlassungen in mehr als 30 Ländern weltweit präsent. Das im TecDAX® und SDAX® an der Deutschen Börse gelistete Unternehmen ist einer der führenden Anbieter von IoT (Internet of Things) Technologien. In diesen Bereichen konzentriert sich S&T auf die Entwicklung sicherer und vernetzter Lösungen durch ein kombiniertes Portfolio aus Hardware, Middleware und Services. Eigentechnologien in den Bereichen Smart Factory, Zugfunksysteme, Medizintechnik, Kommunikationslösungen und Smart Energy sowie ein breites Portfolio an IT-Dienstleistungen machen S&T zu einem gefragten Partner für Kunden unterschiedlichster Branchen.

>> Besuchen Sie 64 weitere Partner auf boerse-social.com/partner


Mehr aktuelle OTS-Meldungen HIER

Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten


Ausgewählte Events von BSN-Partnern


Meistgelesen
>> mehr





PIR-Zeichnungsprodukte


Newsflow
>> mehr

Börse Social Club Board
>> mehr
    #gabb #1236

    Featured Partner Video

    Gedenkkultur und Torrekord

    Das Sporttagebuch mit Michael Knöppel - 9. November 2022 E-Mail: sporttagebuch.michael@gmail.com Instagram: @das_sporttagebuch Twitter: @Sporttagebuch_
    Das Sporttagebuch mit Michael Knöppel - 9...

    Books josefchladek.com

    Will Anderson
    Death In A Good District
    2015
    Yewtree Press

    Matt Dunne
    The Killing Sink
    2022
    Void

    Momo Okabe
    Bible
    2014
    Session Press

    Douglas Stockdale
    Bluewater Shore
    2017
    Self published

    Katrien de Blauwer
    Les photos qu’elle ne montre à personne
    2022
    Éditions Textuel

    Semperit with record earnings in the first nine months of 2020


    19.11.2020, 12845 Zeichen

    Corporate news transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.– annual forecast increased several times due to pandemic-related exceptionalboom and...

    ...successesQuarterly ReportVienna -Consolidated revenue slightly increases by 0.8% to EUR 657.2 million\nStrong increase in revenue in the Medical Sector (+27.5%) somewhat overcompensated the decrease in the Industrial Sector (-13.4%) in absolute figures\nEBITDA almost doubled to EUR 118.5 million; EBITDA margin at 18.0% after 9.3% also almost twice as high\nEBIT significantly improved to EUR 159.9 million in the first three quarters due to reversal of impairment in the Sempermed segment; EBIT margin increased from -2.1% to 24.3%\nAdjusted EBIT of EUR 92.6 million more than tripled\nAnnual forecast for 2020 repeatedly revised upwards\nEarly repayment of hybrid capital planned\n19 November 2020 - As a result of the pandemic-related exceptional boom inmedical protective gloves, the consistent restructuring and transformationprocess over several years and the strict and immediate cost-cutting measures tocontain the negative external market shock caused by CoViD-19 in the IndustrialSector, the Semperit Group achieved a record result in the first nine months of2020 while at the same time significantly increasing the Group's liquidity. "Sofar, Semperit has very successfully coped with the year 2020, which ischaracterised by an absolutely exceptional situation: this has become visible,among other things, in the three-fold improvement in the earnings forecast andour plan to repay the hybrid capital within the next six months," says MartinFüllenbach, CEO of Semperit AG Holding.Further earnings improvement possible in 2021"The positive developments are primarily due to the exceptional boom in medicalproducts. However, they are also the result of comprehensive restructuringmeasures as well as stringent crisis management throughout the Semperit Group,"Füllenbach continued. "Even if a broadly effective vaccine against CoViD-19becomes available in the foreseeable future, we will experience pandemic-relatedpositive effects from the medical business well into 2021: all in all, fromtoday's point of view, our planning is therefore based on the assumption that wewill be able to maintain the 2020 result in the coming year at the same range oreven surpass it again."Slow market recovery expectedAlthough a brief recovery of economic activities and supply chains began betweenJune and September following the easing of production freeze in many countriesand the disruption of public life, there were repeated setbacks and, in somecases, new shutdowns due to regional corona clusters. As the crisis intensifiesagain in the fourth quarter, the recovery of the markets will take even longerwith increasing raw material prices. The prices of basic raw materials relevantto Semperit have risen sharply in recent months. These market-relevant externalfactors will continue to impact the business of the Semperit Group.Opposing revenue trends in Industrial and Medical SectorsThe results of the Industrial Sector have been reported under the new structuresince 1 January 2020. The Sector now consists of four segments (Semperflex,Sempertrans, Semperseal and Semperform), after Semperform was divided into twoseparate segments: Semperseal deals with sealing profiles and elastomer sheets,while Semperform comprises the business units handrails, cable car rings, skifoils and Engineered Solutions (SES).In the first three quarters of 2020, the Semperit Group recorded a slightincrease of 0.8% to EUR 657.2 million compared with the same period of theprevious year. The corona pandemic again had opposite effects on the SemperitGroup's Industrial and Medical Sectors: in the Industrial Sector, revenuedeclined by 13.4%, while the Medical Sector recorded an increase of 27.5%.Record result with high liquidityEBITDA almost doubled in the first three quarters from EUR 60.4 million in 2019to EUR 118.5 million in 2020. This is particularly due to the good result of theMedical Sector, which is based on the exceptional economic boom caused by thecorona pandemic on the one hand and on the successful restructuring andtransformation measures on the other. The EBITDA margin rose accordingly from9.3% to 18.0%. Compared to the EBITDA of EUR 56.4 million in the first threequarters of 2019, adjusted for the reversal of provisions of EUR 4.0 million,EBITDA was more than twice as high in the same period of 2020.At the end of the second quarter, the outbreak of the corona pandemic, whichoccurred during a phase of global economic slowdown, made it necessary toexamine all segments of the Semperit Group for the existence of observableindications of an impairment of segment assets. For the Sempermed andSempertrans segments, this examination resulted in a reversal of impairment (ofEUR 86.7 million) and an impairment loss (of EUR -19.9 million), which werealready recognised in the first half of the year.EBIT improved to EUR 159.5 million in the first three quarters of 2020, comparedto EUR -13.7 million in the first three quarters of 2019. The EBIT margin rosefrom -2.1% to 24.3%. EBIT adjusted for the reversal of impairment and impairmentlosses was EUR 92.6 million, more than three times as high as in the first threequarters of 2019 (EUR 29.0 million). At 14.1%, the adjusted EBIT margin was alsoaround three times the value for the comparable period.At EUR 17.4 million, cash-relevant investments in tangible and intangible assetsin the first three quarters were below the previous year's level of EUR 25.1million. As of 30 September 2020, cash and cash equivalents amounted to EUR157.3 million, up from EUR 141.4 million at the end of 2019. The increaseresulted from higher profitability - above all in the Sempermed segment.Restructuring measures make Industrial Sector resilientThe Industrial Sector was impacted by both the economic downturn that has beenapparent since 2019 and the corona effects. Revenue in the Sector therefore fellby -13.4% from EUR 426.2 million to EUR 369.0 million. The previously introducedrestructuring and transformation measures - as well as the measures to combatthe corona pandemic, increased customer proximity, even in the crisis situation,and strict cost management - partially offset the negative effects.The Industrial Sector was well prepared for the economic slowdown in 2020.Profitability was slightly above the previous year's level and therefore showeda resilient performance. Although EBITDA declined by -12.6% to EUR 65.3 milliondue to the decline in revenue, the EBITDA margin rose slightly to 17.7% in thefirst three quarters of 2020. EBIT declined by 51.1% to EUR 26.9 million and theEBIT margin fell from 12.9% to 7.3% in the first three quarters of 2020. At EUR46.8 million, adjusted EBIT was 14.9% below the previous year's level; at 12.7%,the adjusted EBIT margin was only slightly below the comparable value.Medial Sector: strengthened by restructuring and high demandThe development of the Sempermed segment in the first nine months of 2020 wascharacterised by two key factors. On the one hand, production volumes andoperational efficiency were increased as a result of the successfulrestructuring and transformation measures. On the other hand, as a result of thecorona pandemic, the significant increase in demand for examination andprotective gloves as well as surgical gloves - especially since the secondquarter - and the market-driven rise in price levels were decisive for theresult. Sales volumes rose significantly, with revenue growing by 27.5% to EUR288.2 million compared to the previous year.In addition to the positive corona effect, the measures of the restructuring andtransformation process in the Medical Sector showed their positive effects notonly in terms of production volume and increase in revenue, but also in terms ofproductivity and profitability: in the first three quarters of 2020, EBITDA wasEUR 67.3 million after EUR 5.6 million in the first three quarters of 2019,which also included a positive one-off effect of EUR 4.0 million from thereversal of a provision for tax proceedings relating to levies in Brazil. As aresult of the additional positive effect of the reversal of impairments, EBITamounted to EUR 147.5 million after EUR -47.2 million in the first threequarters of 2019, when an impairment loss of EUR 46.8 million had to berecorded. The EBIT adjusted for the reversal of impairment also improvedsignificantly to EUR 60.7 million compared to the adjusted EBIT of the previousyear (EUR -4.5 million), while the adjusted EBIT margin of 21.1% was above theprevious year's level (in the first three quarters of 2019: -2.0%).OutlookThe recessive economic development and the effects of the corona crisis lead toopposing developments in the Industrial and Medical Sectors: In the medicalprotective gloves business, a significant increase in demand and a sharp rise inprices have been observed since the outbreak of the corona crisis.The emerging effects of the global pandemic are considered to be of limitedsustainability. For this reason, the fundamental strategic decision of 28January 2020, according to which Semperit will focus on the industrial rubberbusiness in the future and separate from the medical business, is still valid,regardless of the developments recently observed in the wake of the coronacrisis. However, in view of the extremely positive earnings contributions andthe high margins that are currently resulting from the exceptional economicsituation, the Semperit Group will probably continue the medical business atleast until mid-2021.The Industrial Sector was hit by the global recession, which has worsened inrecent months due to the corona crisis. The results of the Industrial Sector inthe current year will therefore be noticeably below the previous year's level.The accelerating CoViD pandemic has a more positive effect on the demand andprice of medical products than expected in the first half of 2020. Against thisbackground and assuming the continued uninterrupted availability of rawmaterials, current figures indicate that the Semperit Group's EBITDA for thefull year will range between EUR 200.0 and 225.0 million and thus significantlyexceed the previous year's figure. The Semperit Group's EBIT is thereforeexpected to be between EUR 230.0 and 255.0 million for the full year 2020.In the first three quarters, the boom in the Medical Sector had positive effectson the liquidity of the Semperit Group. The Executive Board of Semperit AGHolding therefore plans to repay the hybrid capital made available by the coreshareholder B & C Holding Österreich GmbH within the next six months.The restructuring and transformation process initiated by the Semperit Group atthe beginning of 2018, which has led to significant improvements at variouslevels, has been further accelerated by the corona crisis. In this context, thefocus on cost-cutting measures will be sharpened again in the coming months.The Semperit management continues to monitor the situation very closely. Thegreatest threat is that a critical number of employees in key areas of the valuechain at one location may not be available due to infection with the coronavirus. In the Industrial Sector, the greatest discernible risk comes frompotential slumps in demand. In the Medical Sector, the current positivedevelopment may be slowed down by the early availability of a vaccine or themarket entry of new competitors. Ensuring the availability of raw materialsdepends on external factors and is the focus of the Semperit Group's purchasingorganisation. The decision on the payment of a dividend for 2020 is yet to bemade. In addition, the Executive Board of Semperit AG Holding now plans to repaythe hybrid capital provided by the core shareholder B & C Holding ÖsterreichGmbH within the next six months.From today's perspective, the outlook for 2021 is also positive: even if abroadly effective vaccine against CoViD-19 becomes available in the foreseeablefuture, the pandemic-related positive effects from the medical business areexpected to extend well into 2021. Based on planning assumptions, the ExecutiveBoard assumes from today's perspective that the 2020 result may be maintained atthe same level or even exceeded in the coming year.end of announcement euro adhocissuer: Semperit AG Holding Modecenterstrasse 22 A-1030 Wienphone: +43 1 79 777-310FAX: +43 1 79 777-602mail: judit.helenyi@semperitgroup.comWWW: www.semperitgroup.comISIN: AT0000785555indexes: WBI, ATX GP, ATX PRIMEstockmarkets: Wienlanguage: EnglishDigital press kit: http://www.ots.at/pressemappe/2918/aom

    Börse Social Network Subscription

    Um diesen Artikel zu lesen, müssen Sie eine Mitgliedschaft erwerben.

    Tagespass 8.00 Euro /einmalig

    15.00 Euro /monatlich



    BSN Podcasts
    Christian Drastil: Wiener Börse Plausch

    Austrian Stocks in English: ATX drops Week 48, Rosinger Group receives Award from the EU, hear a live entry into the ceremony




    Semperit
    Akt. Indikation:  19.16 / 19.26
    Uhrzeit:  18:58:35
    Veränderung zu letztem SK:  0.16%
    Letzter SK:  19.18 ( 0.10%)



     

    Bildnachweis

    1. Judit Helenyi, Semperit AG Holding , (© CIRA/APA-Fotoservice/Bargad Fotograf/in: Nadine Bargad)   >> Öffnen auf photaq.com

    Aktien auf dem Radar:Telekom Austria, FACC, OMV, Addiko Bank, Flughafen Wien, Amag, Frequentis, Mayr-Melnhof, AMS, S Immo, VIG, Wienerberger, Andritz, Kostad, Lenzing, Warimpex, Oberbank AG Stamm, Erste Group, Österreichische Post, Polytec Group, RBI, Rosenbauer, Uniqa, voestalpine, Zalando, Airbus Group, SAP, Fresenius Medical Care, Henkel, Deutsche Boerse, Beiersdorf.


    Random Partner

    S&T AG
    Der Technologiekonzern S&T AG ist mit rund 6.300 Mitarbeitern und Niederlassungen in mehr als 30 Ländern weltweit präsent. Das im TecDAX® und SDAX® an der Deutschen Börse gelistete Unternehmen ist einer der führenden Anbieter von IoT (Internet of Things) Technologien. In diesen Bereichen konzentriert sich S&T auf die Entwicklung sicherer und vernetzter Lösungen durch ein kombiniertes Portfolio aus Hardware, Middleware und Services. Eigentechnologien in den Bereichen Smart Factory, Zugfunksysteme, Medizintechnik, Kommunikationslösungen und Smart Energy sowie ein breites Portfolio an IT-Dienstleistungen machen S&T zu einem gefragten Partner für Kunden unterschiedlichster Branchen.

    >> Besuchen Sie 64 weitere Partner auf boerse-social.com/partner


    Mehr aktuelle OTS-Meldungen HIER

    Useletter

    Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

    Newsletter abonnieren

    Runplugged

    Infos über neue Financial Literacy Audio Files für die Runplugged App
    (kostenfrei downloaden über http://runplugged.com/spreadit)

    per Newsletter erhalten


    Ausgewählte Events von BSN-Partnern


    Meistgelesen
    >> mehr





    PIR-Zeichnungsprodukte


    Newsflow
    >> mehr

    Börse Social Club Board
    >> mehr
      #gabb #1236

      Featured Partner Video

      Gedenkkultur und Torrekord

      Das Sporttagebuch mit Michael Knöppel - 9. November 2022 E-Mail: sporttagebuch.michael@gmail.com Instagram: @das_sporttagebuch Twitter: @Sporttagebuch_
      Das Sporttagebuch mit Michael Knöppel - 9...

      Books josefchladek.com

      Jean-Philippe Charbonnier
      Chemins de la vie
      1957
      Editions du Cap

      Mimi Plumb
      The Golden City
      2021
      Stanley / Barker

      Raymond Meeks
      Halfstory Halflife
      2018
      Chose Commune

      Will Anderson
      Death In A Good District
      2015
      Yewtree Press

      Douglas Stockdale
      Bluewater Shore
      2017
      Self published